Medtronic PLC $MDT Shares Purchased by Barclays PLC

Key Points

• Barclays PLC boosted its Medtronic stake by 104.6% in Q3, buying an additional 3,492,192 shares to hold 6,831,203 shares (about 0.53% of the company) valued at roughly $650.6 million.
• Medtronic declared a quarterly cash dividend of $0.71 ($2.84 annualized, ~3.1% yield) payable April 17 with record/ex‑dividend date March 27, reinforcing its dividend‑growth profile.
• Medtronic’s diabetes unit MiniMed priced a U.S. IPO raising about $560 million, a spin‑out that market participants warn could create near‑term selling pressure on MDT as diabetes growth and cash flows shift away from the parent.

Barclays PLC boosted its holdings in Medtronic PLC (NYSE:MDT - Free Report) by 104.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 6,831,203 shares of the medical technology company's stock after buying an additional 3,492,192 shares during the period. Barclays PLC owned approximately 0.53% of Medtronic worth $650,604,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Delos Wealth Advisors LLC purchased a new stake in Medtronic during the 2nd quarter worth $27,000. Corundum Trust Company INC purchased a new position in Medtronic in the 3rd quarter valued at about $27,000. Valley Wealth Managers Inc. acquired a new stake in shares of Medtronic during the third quarter valued at about $29,000. Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Medtronic during the third quarter valued at about $33,000. Finally, Tripletail Wealth Management LLC purchased a new stake in shares of Medtronic during the third quarter worth about $34,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Board approved a cash dividend of $0.71 for Q4 FY2026, reinforcing Medtronic’s long track record as a dividend grower and supporting income‑focused investor demand. Medtronic announces cash dividend for fourth quarter of fiscal year 2026
• Positive Sentiment: Medtronic launched the MiniMed Go Smart MDI system with the Simplera sensor in Europe, expanding its connected diabetes portfolio and addressing long‑term growth in continuous glucose monitoring and smart‑pen integration. Medtronic’s New MiniMed Go Highlights Digital Diabetes Push And Valuation Gap
• Positive Sentiment: Medtronic and GE HealthCare expanded their patient‑monitoring alliance, which could broaden distribution for products like Nellcor pulse oximetry and support recurring revenue streams. Medtronic, GE HealthCare expand patient monitoring alliance
• Positive Sentiment: Industry reports continue to rank Medtronic among leaders in biosensors and continuous glucose monitoring, supporting the company’s strategic position in a fast‑growing addressable market. Biosensors Company Evaluation Report 2025
• Neutral Sentiment: MiniMed priced its IPO at $20.00 per share for 28,000,000 shares — a procedural step that establishes a public valuation for the diabetes unit but doesn’t by itself show how Medtronic will deploy proceeds or adjust ownership. MiniMed announces pricing of initial public offering
• Negative Sentiment: MiniMed’s US IPO raised roughly $560 million — the market is interpreting the spin‑out as a catalyst for MDT selling pressure because it shifts future diabetes growth and cash flows away from the parent and may prompt portfolio rebalancing by investors. Medtronic's diabetes unit MiniMed raises $560 million in US IPO

Medtronic Stock Performance

Shares of NYSE MDT opened at $92.96 on Friday. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The company has a market cap of $119.35 billion, a PE ratio of 25.89, a P/E/G ratio of 2.40 and a beta of 0.71. The stock has a 50 day simple moving average of $98.80 and a 200-day simple moving average of $96.95. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT - Get Free Report) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm had revenue of $9.02 billion for the quarter, compared to analysts' expectations of $8.89 billion. During the same period last year, the firm earned $1.38 EPS. The firm's revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be issued a $0.71 dividend. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.1%. Medtronic's dividend payout ratio is presently 79.11%.

Analyst Ratings Changes

MDT has been the topic of several analyst reports. JPMorgan Chase & Co. dropped their price objective on Medtronic from $105.00 to $100.00 and set a "neutral" rating on the stock in a report on Wednesday, February 18th. Leerink Partners decreased their price target on shares of Medtronic from $120.00 to $119.00 and set an "outperform" rating for the company in a research report on Wednesday, February 18th. Truist Financial cut their price target on shares of Medtronic from $107.00 to $103.00 and set a "hold" rating on the stock in a report on Wednesday, February 18th. TD Cowen reiterated a "buy" rating on shares of Medtronic in a research note on Friday, November 14th. Finally, Wells Fargo & Company assumed coverage on shares of Medtronic in a report on Friday, January 30th. They set an "overweight" rating and a $114.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $110.74.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the transaction, the executive vice president owned 32,768 shares in the company, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.26% of the stock is owned by corporate insiders.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.